Craft
  • Home
  •  / Biological E
Biological E

Biological E

Revenue

₹9.3 B

FY, 2019

Biological E Summary

Company summary

Overview
Biological E (also known as BE, formerly Biological Products Private) is a biological products and pharmaceuticals company that manufacturer and supplies vaccines. It operates 4 strategic business units: Branded Formulations, Speciality Generic Injectables, Synthetic Biology, and Vaccines and Biologics. The Branded Formulations unit supplies Heparin and Noscapine-based cough medications. The Speciality Generic Injectables unit develops and commercializes injectable products, primarily non-biological complex drugs, as well as complex and routine injectable products. The Synthetic Biology unit is focused on making active pharmaceutical ingredients (APIs) using synthetic biology. The Vaccines and Biologics unit produces Tetanus, Pentavalent, Polyvalent Snake Antivenom, and other vaccines.
Type
Private
Founded
1953
HQ
Hyderabad, IN | view all locations
Website
https://www.biologicale.com/
Cybersecurity rating
Sectors

Key people

  • Mahima Datla

    Mahima Datla, Managing Director & CEO, Vaccines & Branded Formulations

  • Lakshminarayana Neti

    Lakshminarayana Neti, COO, Vaccines & Branded Formulations

  • Narender Dev Mantena

    Narender Dev Mantena, Head, Global Strategy & CEO, Specialty Generic Injectables & Synthetic Biology

    • Madhusudan Rao

      Madhusudan Rao, COO, Specialty Generic Injectables

    Operating MetricsView all

    Vaccines Produced, doses

    483M
    6.9%

    FY, 2019

    Vaccines Sold, doses

    305M
    6.2%

    FY, 2019

    Suppliers

    1.6K
    1.8%

    FY, 2019

    LocationsView all

    5 locations detected

    • Hyderabad, TG HQ

      India

      Rd Number 35, Aditya Enclave, Venkatagiri, Jubilee Hills

    • Cary, NC

      United States

      203 New Edition Ct

    • Hyderabad, TG

      India

      18/1&3, Azamabad, Bharat Nagar

    • Kolthur, TG

      India

      Plot No. 1, Biotech Park, Phase II, Kolthur Village

    • Zug, ZG

      Switzerland

      Rothusmatt 3

    Biological E Financials

    Summary financials

    Revenue (FY, 2019)
    ₹9.3B

    Footer menu